T issue-type plasminogen activator (tPA) is the only Food and Drug Administration-approved drug for treating acute ischemic stroke.
and composition, as well as arterial recanalization and clinical improvement. 4 With few exceptions, we are currently limited to characterizing cerebral thromboemboli in clinic by means of negative contrast.
To overcome many of the pitfalls that current thrombus imaging techniques have (Introduction in the online-only Data Supplement), we have recently developed a direct thrombus imaging technique using computed tomography (CT) and fibrin-targeted glycol chitosan-coated gold nanoparticles (AuNPs). 10 We have noted that since tPA was first introduced in 1996, no study-to our knowledge-has quantitatively assessed a detailed spatial and temporal evolution of cerebral thromboemboli before, during, and after tPA treatment. In the present study, using a mouse model of embolic stroke, we demonstrate that high-resolution in vivo micro-CT (mCT)-based direct thrombus imaging using fibrin-targeted glycol chitosan-coated AuNP enables us to study the tPA-mediated dynamic evolution of cerebral thromboemboli in a quantitative manner.
Materials and Methods
This study was approved by the Institutional Animal Care and Use Committee at Dongguk University Ilsan Hospital, and all experiments were conducted in accordance with the institutional guidelines on humane care and use of laboratory animals. Embolic stroke was induced (n=50 mice), as previously reported 11 with some modification, 10 by injecting preformed fluorescently marked clots into the middle cerebral artery-anterior cerebral artery bifurcation area using a catheter placed in the distal common carotid artery after insertion through a hole made in the external carotid artery. One hour later, mCT images were acquired 5 minutes after intravenous administration of 300 μL fibrin-targeted glycol chitosan-coated AuNPs 10 that we synthesized. These animals were then treated intravenously with either 1 mg/mL tPA (25 mg/kg, 600 μL) or saline (600 μL) bolus injection (10%), which was followed by continuous infusion (90%) for 30 minutes. Serial mCT images were acquired immediately after the bolus (designated as 0 hour) and at 0.5, 1, 1.5, 2, 3, and 24 hours after the bolus/start of the infusion. Once the scheduled imaging sessions were completed, brains were harvested and immediately imaged using a near-infrared fluorescence (NIRF) imager to use the area of thrombus-related fluorescent signal as a reference value to be compared with the area of hyperdense marked thrombus on mCT. Then, 2,3,5-triphenyl-tetrazolium chloride staining was performed to delineate infarcted areas. Finally, quantitative image analyses and infarct mapping were performed. More details are available in the Methods (including Figure I) in the online-only Data Supplement.
Results

Total Thrombus Burden and Thrombolysis
The total thrombus burden prior to therapy was 784×10 24 Hours Thrombolytic therapy was initiated 1 hour after thrombus deposition, but the thrombus area of the entire brain did not significantly change until 30 minutes after tPA (Figure 1) . Specifically, the thrombus area did not significantly reduce either after tPA loading or during the subsequent 30-minute infusion (both corrected P [P corr ]>0.05]. One hour after tPA administration began, the thrombus area became significantly smaller than baseline (P corr <0.01). This indicates a lag time between the start of tPA treatment and the initial thrombolytic effect, which appeared somewhere between the 0.5-and 1-hour time points (Figures 1 and 2) . The thrombus reduction rate between those time points was 4603±957 μm 2 /min, as calculated by ([area 0.5 h -area 1 h ]/time) and was the highest rate of change throughout the 24-hour measurement period (Figure 2 ).
During the 2 hours after this initial high-change phase, thrombus area reduction continued but at a lower rate of change. About 61% of the first thrombolytic effect (ie, 39% lower than the initial thrombus reduction rate) occurred 1 to 2 hours after the start of tPA and ≈29% (ie, 71% lower than the initial rate) during hours 2 to 3.
Thrombolysis continued at later times, though much weaker. More specifically, thrombus area reduction sustained out to 24 hours, but the rate of change was as low as 57±20 μm 2 /min during hours 3 to 24, which is only ≈1% of the strong primary thrombolytic effect observed during 0.5-to 1-hour period. During hours 3 to 24, however, a considerable amount of thrombus was dissolved, so that the thrombus area was significantly reduced from 359×10 
±56×10
3 μm 2 to 287×10 3 ±54×10 3 μm 2 (P corr =0.02). In other words, of ≈500×10 3 μm 2 thrombus (≈64% of the baseline burden) that was dissolved in the 24 hours after tPA therapy, ≈85% was cleared during the first 3 hours, while the other 15% was cleared during the next 21 hours.
Unlike tPA treatment, saline treatment did not show significant change in the thrombus area (Figure 1 ; Figure II We observed no significant correlation between the initial thrombolytic effect and any subsequent thrombus reduction rates, that is, at hours 1 to 1.5, 1.5 to 2, 2 to 3, or 3 to 24 hours (all P>0.05; data not shown), thereby indicating that the earliest evidence of significant thrombolysis did not predict continued thrombolysis at later time points. However, there was a modest correlation between the thrombus reduction rates at hours 1.5 to 2 versus those at hours 3 to 24 (r=0.68; P<0.01; Figure IIIA in the online-only Data Supplement). This relationship indicates that relatively early, although not the earliest, evidence of thrombolysis may predict continued thrombolysis later on. In addition, the linear associations between the thrombus areas at 24 hours versus prior time points (ie, baseline to 3 hours) tended to strengthen gradually over time and plateau at 2 hours ( Figure IIIB in the onlineonly Data Supplement). As shown in Figure IIIC and IIID in the online-only Data Supplement, mCT-measured thrombus burden ≈2 hours after the start of tPA therapy strongly predicts thrombus burden at both 3 hours (r=0.92; P<0.01) and 24 hours (r=0.89; P<0.01).
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Thrombolysis in the Circle of Willis and Its Subregions
The circle of Willis (COW) thrombus burden prior to therapy was 535×10 Microcomputed tomography (mCT)-based direct thrombus imaging serially and quantitatively assesses the location, amount, and evolution of cerebral thromboemboli in response to the thrombolytic effects of tissue-type plasminogen activator (tPA). A and B, Representative serial mCT images. Baseline mCT thrombus imaging was performed 5 minutes after intravenous injection of fibrin-targeted gold nanoparticles and 1 hour after embolic stroke. Direct thrombus imaging permits the localization and quantification of cerebral thrombi. Serial mCT imaging showed no change in the thrombus after saline treatment (A). However, tPA treatment initiated immediately after baseline imaging (total dose of 1 mg/mL tPA administered as a 60 μL bolus injection followed by 540 μL continuous infusion over 30 minutes) showed gradual thrombus dissolution (arrowheads on B). This demonstrates that thrombus marking can allow therapeutic monitoring of thrombolysis. Infarct size on 2,3,5-triphenyl-tetrazolium chloride (TTC) staining (rightmost panels of A and B) showed a corresponding reduction in the amount of infarcted brain. Note that after tPA treatment near-complete thrombus resolution in the circle of Willis and posterior cerebral artery (red arrowheads in B) is accompanied by the distal migration of scattered emboli (yellow arrowheads in B). C, Grouped quantification data for the entire brain in all animals (n=50; 42 tPA and 8 saline treatments). tPA reduced the amount of thrombus over time and reached significance 0.5 hours after the end of the 30-minute infusion (ie, 1 hour after tPA treatment initiation and 2 hours after embolic stroke vs baseline). Thereafter, thrombus area reduced further out to 24 hours (vs 3-hour time point). There was no significant change in the thrombus area during the same period in the saline-treated animals. D, Infarct size at 24 hours as per quantitative brain mapping of TTC-stained sections from 2-mm-thick sections, taken at 0.98, −1.06, and −3.08 mm distance from the bregma, that correspond to the 3 coronal brain sections (blue squares) in (A and B). The final infarct size is significantly smaller in the tPA-treated animals than in the saline-treated animals. Graphs show mean±SEM. *P<0.01 and # P<0.05 by generalized estimating equation method and Bonferroni correction for multiple comparisons between thrombus areas at 2 different time points ('adjacent' or 'baseline vs later' time points) within each of the tPA and saline groups. Red and blue lines (in C) connect the means. Scale Bars=2 mm. Supplement). However, during the first 3 hours after saline loading and infusion, there was an 8.5±2.7% increase in COW thrombus area, as compared with pretreatment baseline (P corr <0.01; Figure IVA in the online-only Data Supplement). In addition, tPA showed a largely homogeneous thrombolytic effect in the COW's Y-shaped thrombus subregions (Figures 3 and 4 ; Figure V and Results in the online-only Data Supplement).
Thrombolysis in the Cerebral Arteries Distal to the COW
Prior to therapy, the thrombus burden in the distal arteries was 249×10 3 ±34×10
3 μm 2 for the tPA group and 148×10 3 ±76×10 3 μm 2 for the saline group (P=0.24). Though the distal cerebral arteries had significant thrombus reduction, the rate of reduction was generally lower, started later, terminated earlier, and showed a smaller initial thrombolytic effect than in the COW (Results in the online-only Data Supplement).
Infarct Size and Relationship to Thrombus and Thrombolysis
Ex vivo thrombus imaging and histological studies confirmed the tPA-mediated therapeutic effects on cerebral thromboemboli and infarcts, respectively. mCT imaging showed that saline-treated animals had ≈3.5-fold larger thrombus areas in the COW at 24 hours than the tPA-treated animals (488±94 versus 145±41 μm 2 ; P<0.01). This was confirmed by ex vivo NIRF thrombus imaging ( Figure 5A ), which showed that tPAtreated animals had ≈3-fold larger COW thrombus areas than the control animals (505±91 versus 168±37 μm Figures 1 and 5B ). In addition, there was a strong correlation between thrombus areas as measured by mCT and NIRF imaging (r=0.81; P<0.01; Figure 5C , left). There was also a relatively strong correlation between infarct areas and mCT-measured COW thrombus areas (r=0.71; P<0.01; Figure 5C , middle). This correlation was stronger than that between infarct areas and NIRF imaging-measured COW thrombus areas (r=0.57; P<0.01; Figure 5C , right), likely because mCT was more accurate than NIRF imaging in estimating total thrombus burden. On the other hand, microscopic NIRF imaging could detect microvascular emboli, as well as bigger clots (Figure VI in the online-only Data Supplement).
Infarct Size Was Smaller When Thrombus Clearance Occurred Earlier
Within the tPA-treated cohort, final infarct size was smaller when complete thrombus clearance occurred earlier in the COW arteries ( Figure 6 ). COW thrombi that were completely dissolved during hours 0.5 to 1 or hours 1 to 2 after the beginning of tPA infusion (n=7 and 5, respectively) had smaller infarcts (3.3±0.9 and 8.3±0.5 mm 2 ) than those cleared between hours 1 to 2 or hours 2 to 3 (n=8, 13.3±1.2 mm 2 ), respectively (all P<0.01; Figure 6 ). Further, infarct size was smaller when thrombus was cleared during hours 1 to 2 (n=5, 8.3±0.5 mm 
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May 2017 mm 2 ), tPA-mediated complete thrombus clearance beyond the therapeutic window (between 3 and 24 hours) did reduce infarct size significantly (n=8, 17.1±2.0 mm 2 ; P<0.01). This result suggests that even late thrombus clearance can help reduce infarct size ( Figure 6 ). Not one of the saline-treated animals (n=8) cleared thrombus by 24 hours, and their infarct sizes (45.8±3.3 mm 2 ) were significantly larger, even when compared with the tPA group animals without thrombus clearance by 24 hours (P=0.04). It seems that even when thrombus failed to clear in tPA-treated animals within our measurement period, some residual benefit remains.
Among the animals without complete thrombus clearance in the COW by 24 hours, tPA-treated animals (n=14) had ≈30% smaller infarcts (32 
Multivariable Analysis Showed That Infarct Size Was Smaller When Thrombus Cleared More Completely
mCT imaging detected not only residual thrombus in the COW but also scattered emboli in the distal vasculature across both hemispheres, particularly after tPA therapy (Figure 1, yellow  arrowheads) . Furthermore, multivariable analyses demonstrated that tPA (versus saline) treatment, thrombus clearance time, and residual thrombus burden in either the COW or the entire brain independently predicted the final infarct size (Table in the 
Discussion
This is the first in vivo imaging study to directly visualize cerebral thromboemboli in a relatively large number of animals (n=50 mice) serially (at 8 time points/24 hours) in a quantitative manner by using high-resolution mCT and fibrin-targeted 
AuNPs
10 that we recently developed. No significant thrombus reduction could be observed until 1 hour after the initiation of tPA therapy at 1 hour after stroke. Most thrombolysis occurred within 3 hours of tPA therapy onset, with stronger observable effects within the 1-to 3-hour period. Thereafter, we noted further minor thrombus reduction until 24 hours, ≈15% (versus prior 85%) of the total clearance, more so in the COW than in the distal arteries. By allowing quantitative assessments of early thrombolytic effect and residual thrombus burden, mCT imaging helped predict continued thrombolysis at later time points. Infarct size was smaller when thrombus was cleared earlier and more completely; however, late thrombus clearance and tPA use alone also reduced infarct size. Saline treatment was not associated with significantly decreased thrombus area.
Our novel understanding of the dynamic evolution of cerebral thromboemboli is highly significant, and if these findings translate to humans, our results would suggest time points for monitoring therapeutic success and provide thresholdsstill within the therapeutic window-at which a lack of success would prompt additional treatment. In addition, our data indicate intersubject heterogeneity in the thrombus's spatiotemporal response to tPA. This variable therapeutic response highlights the need for direct thrombus imaging to individualize thrombolytic therapy.
In our previous study, ex vivo NIRF imaging of brain tissue removed 24 hours after embolic stroke showed that thrombus burden in the COW closely correlated with final infarct volume as measured by 2,3,5-triphenyl-tetrazolium chloride staining. 12 In the present study, using in vivo mCT-based direct thrombus imaging and fibrin-targeted AuNPs allowed us to (1) promptly detect cerebral thrombus, (2) accurately quantify thrombus burden, and (3) serially monitor thrombus evolution in response to fibrinolytic (versus saline) therapy. Further, multivariable analysis identified 3 independent predictors of final 
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May 2017 infarct size. These data provide quantitative support for the well-accepted notion that early flow restoration is vital to successfully treating stroke (time is brain; standardized |β| for the model I =0.40), followed by lysis completion level (|β|=0.37), with smaller residual thrombi associated with smaller final infarct size, and, finally, tPA therapy by itself (|β|=0.35).
In the intravenous tPA-treated animals, but not the salinetreated controls, thrombolysis also occurred 3 to 24 hours posttreatment, which is far beyond the tPA's 5-to 10-minute blood half-life. 13 Although it is unclear when exactly the tPA effect disappeared during hours 3 to 24, this prolonged thrombolytic effect may be because of continuously uninhibited activity of the exogenous tPA that was bound to the thrombi's fibrin meshwork. Once tPA-mediated recanalization begins, clots soften and partially dissolve, thereby allowing some (often minimal) residual flow improvement. The reconstituted flow delivers more tPA to bind with fibrinogen sites. This continuous process facilitates clot lysis and improves residual flow until the clot finally breaks up under the pressure of arterial blood pulsations. 6 In addition, tPA-aided spontaneous lysis could have enabled the delayed thrombolysis. Exogenous tPA may have modified thrombi to have a greater surface areas and relatively loose fibrin meshwork, so that locally released endogenous tPA could better penetrate the thrombi. 14 In addition to thrombolysis effectiveness and time point thereof, infarct size also varied because of residual thromboemboli burden at 24 hours, probably because of persistent distal arterial occlusion and compromised distal perfusion. Clinically, persistent distal emboli are frequently observed in mechanical thrombectomy cases. 15 Moreover, small emboli that could be related to poor clinical outcomes may not be noticeable on traditional angiographic imaging. 15, 16 Distal flow disturbances can also be caused by stagnant flow in the distal microcirculatory bed; potential mechanisms for such stagnant flow include activated platelet aggregation, leukocyte activation, local accumulation of inflammatory mediators, edema, and other factors that affect ischemic brain tissue, and endothelial function. 6, 17 These factors may explain why arterial recanalization does not always lead to brain tissue reperfusion. 18 Recanalization and reperfusion are not synonyms and should not be used interchangeably in predicting infarct size. 19 Experimental studies on thrombolysis have demonstrated that effective delivery of fibrinolytic agents into thrombi by diffusion and convection is the most important determinant of fibrinolytic rate, which is highest when short clots are exposed to a high pressure gradient. 20, 21 In our study, the thrombolytic effects of tPA were relatively homogeneous for the 4 subregions of the Y-shaped COW thrombus. This observation suggests regionally consistent tPA delivery or subregional access to circulating plasminogen in the COW thrombus. If the proximal internal carotid artery had been severely narrowed or occluded (with collateral blood flow to anterior cerebral artery and middle cerebral artery being preserved or augmented), tPA-mediated thrombolysis may have been much slower and less complete in the distal intracranial internal carotid artery than in the other subregions of the COW. In addition to the hindered dissolution of clot, reduced perfusion pressure because of internal carotid artery steno-occlusion also causes hemodynamic instability, increasing the risk of rethrombosis after incomplete recanalization. 22 On the other hand, hemodynamic manipulations, such as triple-H (hemodilution, hypervolemia, and hypertension) therapy, might possibly allow improved access of tPA to thrombi, and imaging approaches likely allow the success of such therapies to be monitored. Again, CT and nanoparticle-based direct thrombus imaging could provide an early and objective readout of the success of such clinical manipulations.
In the arteries distal to the COW, a significant but lower thrombus reduction rate took longer to begin than in the COW itself. The relatively low thrombus reduction rate in the distal cerebral arteries may be partly because of thrombolysisrelated distal embolism, which may have reduced the proximal thrombus burden while simultaneously increasing the distal thrombus burden.
Ribo et al 8 showed that most tPA-induced recanalization occurred during the first hour after treatment, and patients with delayed flow improvement achieved 48-hour neurological scores comparable to those of patients with early recanalization. 8 Similarly, our animal study showed late thrombus clearance beyond the therapeutic window still significantly reduced infarct size. Against expectations, we found tPA to be therapeutically beneficial even in the absence of thrombus clearance, when compared with saline-treated animals, despite no significant intergroup differences in residual thrombus areas at 24 hours. This protective effect of tPA is both frequent, producing ≈50% more relatively small infarcts, and significant, with infarcts ≈30% smaller. These numbers dwarf the rates of symptomatic intracranial hemorrhage caused by tPA treatment in humans.
In the present study, embolic stroke was induced using erythrocyte-and fibrin-rich clots that were prepared as previously reported. 23, 24 Several studies showed that platelet-rich clots were relatively resistant to thrombolysis, highlighting the importance of clot composition on the efficacy of thrombolytic therapy. 25 Platelet-rich clots may be better mimics of cerebral thrombi retrieved from a subset of stroke patients without recanalization after prior tPA therapy, 25 suggesting a need for further investigation of in situ identification of clot structure to tailor treatment to the patient. Identification of such clots, possibly by using direct thrombus imaging to characterize thrombus composition, may allow early pursuit of endovascular therapy, such as mechanical clot retrieval. 10, 26 In addition, fibrin-targeted glycol chitosan-coated AuNP CT imaging of large vessel occlusion-related thromboembolism is a powerful research tool for development of more rigorous and nuanced diagnostics and therapies for these clots. For example, platelet-rich clots may be more avidly sought out by platelet-targeted imaging agents than fibrin-targeted nanoparticles and might be better treated by therapeutics directed at platelets or fibrin as the case might be. Further studies are required to investigate if direct thrombus imaging using nanoparticles that target fibrin versus platelets could demonstrate differential efficacy of tPA versus eptifibatide or similar treatments.
Our experimental tPA study focused on thromboemboli causing macrovascular occlusion. For further research in the context of large vessel occlusion, it would be interesting to study the pharmacological effect of tPA or a novel drug that targets the thrombotic/inflammatory processes downstream of the culprit clot, the microvascular consequences of thromboembolism. Our study showed that mCT imaging after tPA therapy detected not only residual thrombi at the site of thromboembolic occlusion but also scattered emboli in the distal vasculature in vivo. Moreover, microscopic NIRF imaging of ex vivo brain sections could visualize microvascular emboli because of the fluorescent labeling of the culprit thrombi before being placed in the COW. Emerging experimental evidence suggests that tPA has substantial beneficial effects on the inhibition of downstream postcapillary microvascular thrombosis during occlusion and after recanalization. 27 Large vessel occlusion clots cannot be readily dissolved by tPA in the majority of cases, requiring endovascular therapy. However, the imaging approach we demonstrate in our study with tPA (feasible in rodents) could be used with equal effectiveness in the setting of endovascular therapy (feasible in man) and serves as a proof-of-concept for such future uses.
Despite the long-awaited success of endovascular therapy trials, 28 there is much work remaining 29, 30 on (1) reducing delays to revascularization (because of poor vascular access or interhospital transfers), (2) increasing rates of complete revascularization, 31 (3) decreasing the procedure-related complications (eg, distal embolization), (4) expanding current indications with regards to the time window and ischemic territories, (5) customizing endovascular therapies (eg, selecting best devices for individual cases), and (6) determining the best methods for combined intra-arterial and medical approaches. All of these problems would benefit from improved imaging for triaging and monitoring the efficacy of current and future therapies (Discussion in the online-only Data Supplement).
